Navigation Links
Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
Date:7/22/2009

of novel therapeutics. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design and "Snano" series of nanoparticle delivery systems enable its advanced RNAi therapeutic programs for treatment of various diseases including H1N1/H5N1 influenza A infection, scarless wound healing and several types of cancers.

"Receiving an SBIR grant again from NCI clearly demonstrates the scientific and business merits of our lung cancer therapeutic program using multi-targeted siRNA cocktails," said Dr. Patrick Y. Lu, the founder, President and CEO of the company, also the Principal Investigator of the grant proposal. "It is a successful extension of Sirnaomics product pipeline for siRNA therapeutics." Dr. Lu further emphasized that the grants from various Government agencies provided a sustainable funding resource to the company in addition to its corporate partnership deals and venture capital investments. "Funding from Government is uniquely important for an early stage company like Sirnaomics, especially in the current financial environment."

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established by a group of leading scientists in the field of RNAi technology, the company has a mission of advancing RNAi technology for novel drug discovery and targeted therapeutics development. Members of the senior management team bring over 50 years of combined experience in the biopharmaceutical, financial and business management industries in both the US and China and the company has established a subsidiary in Suzhou, China to expand both its R&D capacity and potential market.

    Contact:
    George J. Ji
    Sirnaomics, Inc.
    401 Professional Drive, Suite 130
    Gaithersburg, MD 20879, USA
    301-740-1730 Phone
    301-740-1731 FAX
    info-office@sirnaomics.com
   '/>"/>
SOURCE Sirnaomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
2. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
3. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
4. TorreyPines Receives Notice of Delisting from Nasdaq Global Market
5. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
6. UCR physicist receives highest honor US government gives young scientists or engineers
7. Professor Fisher receives ASEEs Beer and Johnston Award
8. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
9. Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring System
10. WuXi PharmaTech Receives Award from BASF
11. AEterna Zentaris Receives US$10 Million from Institutional Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Based ... the overall surgical imaging market is dominated by ... the surgical imaging market. These players include GE ... Ziehm Imaging (Germany). , Full Report Copy ... of GE Healthcare can be attributed to its ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... part of Aeterna Zentaris, strategy of personalized approach to treatment ... doxorubicin, being investigated in multiple cancers , ... QUÉBEC CITY, June ... AEZS ), (the "Company"), a late-stage drug development company ...
... June 28 Chiasma, Inc., a privately held biopharma ... drug designation for Chiasma,s investigational new drug, Octreolin, an oral form of ... for the oral treatment of acromegaly, a hormonal disorder that results from ... , , ...
... , June 26, 2010 Amylin Pharmaceuticals, ... an analysis of an integrated database of clinical studies ... associated with SYMLIN® (pramlintide acetate) injection use compared to ... rapid-acting insulin. These findings were presented at the 70th ...
Cached Biology Technology:Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer 2Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer 3Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer 4Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly 2Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly 3Chiasma Receives Orphan Drug Designation From the FDA for Octreolin™ for the Oral Treatment of Acromegaly 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 2Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 3Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 6Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 7
(Date:11/15/2014)... we may still be a few years away from the ... gain instant access to all that ailed his patients, mobile ... for monitoring and measuring our health are cropping up in ... tad Orwellian to some, but a new survey suggests that ... into their healthcare regime. These are some of ...
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... Naturally occurring "keystone" molecules that have powerful behavioral effects ... in structuring ecosystems, according to a theory proposed in ... of the theory, Ryan P. Ferrer of Seattle Pacific ... California at Los Angeles, liken such molecules to keystone ...
... the middle Devonian era some 380 million years ago ... of ecosystems to remain stable in the face of environmental ... online journal PLOS ONE . Trained to examine ... test the stability of Earth,s past ecosystems. The research shows ...
... into the incubation behavior of modern birds is shedding new ... their long extinct ancestors. The study, by researchers at ... to test the hypothesis that data from exisiting birds could ... group of carnivorous dinosaurs from which birds descended. The ...
Cached Biology News:Natural 'keystone molecules' punch over their weight in ecosystems 2Clam fossils divulge secrets of ecologic stability 2Study provides insight into nesting behavior of dinosaurs 2
... submicron range are part of your production ... of particle size is important to you. ... detect the component populations in your sample ... Analyzer uses Photon Correlation Spectroscopy (PCS) , ...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
... 100-120 and 220-240 V, is a microfluidics-based ... gel-based electrophoresis, including some data analysis, in ... for protein analysis (it does not include ... The system includes the electrophoresis station, priming ...
... are preactivated with carbonyl diimidazole chemistry that ... The PS10 array contains the same binding ... with an updated hydrophobic barrier coating. These ... mm diameter spots spatially compatible with one ...
Biology Products: